{
    "Clinical Trial ID": "NCT00428220",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Sunitinib",
        "  Participants receiving treatment on single-agent sunitinib on continuous dosing regimens returned for study visits at Day 28, and every 8 weeks thereafter. Participants on regimens other than single-agent sunitinib on continuous dosing followed the schedule of activities from their parent or extension protocol. Sunitinib-na\u00efve participants (ie, those not treated with sunitinib in the previous parent study) received a starting dose of 37.5 mg sunitinib once daily."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Must have ended treatment from one of the following sunitinib studies: A6181030, A6181064, A6181078, A6181087, A6181094, A6181107, A6181108, A6181110, A6181111, A6181112, A6181113, A6181120, A6181126 and A6181170. Other Pfizer sponsored sunitinib studies may be included in the future.",
        "Exclusion Criteria:",
        "  See inclusion criteria"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Number of Participants With Treatment-emergent Adverse Events (AEs) (All Causalities)",
        "  Assessment of AEs included type, incidence, severity (graded by the National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE], Version 3.0, timing, seriousness, and relatedness; and laboratory abnormalities.",
        "  Time frame: From first day of treatment on the current study up to 28 days post the last dose of study treatment",
        "Results 1: ",
        "  Arm/Group Title: Sunitinib",
        "  Arm/Group Description: Participants receiving treatment on single-agent sunitinib on continuous dosing regimens returned for study visits at Day 28, and every 8 weeks thereafter. Participants on regimens other than single-agent sunitinib on continuous dosing followed the schedule of activities from their parent or extension protocol. Sunitinib-na\u00efve participants (ie, those not treated with sunitinib in the previous parent study) received a starting dose of 37.5 mg sunitinib once daily.",
        "  Overall Number of Participants Analyzed: 223",
        "  Measure Type: Number",
        "  Unit of Measure: participants  Participants with adverse events (AE): 221",
        "  Participants with serious adverse events (SAE): 90",
        "  Participants with grade 3 or 4 AEs: 174",
        "  Participants with grade 5 AEs: 24",
        "  Participants discontinued due to AEs: 67",
        "  Participants with dose reduction due to AEs: 66",
        "  Temporary discontinuations due to AEs: 146"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 90/223 (40.36%)",
        "  Anaemia * 5/223 (2.24%)",
        "  Neutropenia * 1/223 (0.45%)",
        "  Thrombocytopenia * 1/223 (0.45%)",
        "  Acute coronary syndrome * 1/223 (0.45%)",
        "  Acute myocardial infarction * 1/223 (0.45%)",
        "  Myocardial infarction * 1/223 (0.45%)",
        "  Abdominal adhesions * 1/223 (0.45%)",
        "  Abdominal pain * 8/223 (3.59%)",
        "  Abdominal pain upper * 2/223 (0.90%)",
        "  Ascites * 2/223 (0.90%)"
    ]
}